ATS 2020 Advance Program

difficult infections such as empyema, refractory pulmonary MAC, pulmonary TB, and infectious complications of bronchiectasis. This course will provide clinicians with a broad overview of and recent updates on current challenges in pulmonary and critical care infections, including those caused by bacteria, mycobacteria, viruses, and fungal pathogens. General approaches to infections in the immunocompromised host will likewise be discussed. Each talk will begin with a challenging case example followed by a multiple-choice question, which the attendees will answer using an audience response system (ARS). Chairing: O. Epelbaum, MD, ATSF, Valhalla, NY R. Thomson, MBBS, PhD, Greenslopes, Australia C.A. Hage, MD, ATSF, Indianapolis, IN 8:00 Introduction O. Epelbaum, MD, ATSF, Valhalla, NY 8:05 Resistant Pathogens in Severe CAP: Exaggerated or Underestimated? G.W. Waterer, MBBS, MBA, PhD, Perth, Australia 8:30 How Should We Define and Diagnose VAP? R.G. Wunderink, MD, Chicago, IL 8:55 Pleural Space Infection: Medical or Surgical Disease? N. Rahman, BMBCH, MSc, Oxford, United Kingdom 9:20 Panel Discussion 9:35 Break 9:50 Can We Reduce Infectious Exacerbations in Non-CF Bronchiectasis? G. Tino, MD, ATSF, Philadelphia, PA 10:15 What Are the Options for Managing Treatment Failure in Pulmonary MAC? R. Thomson, MBBS, PhD, Greenslopes, Australia 10:40 What Is the Current Role of the Respiratory Clinician in Pulmonary TB? S.E. Dorman, MD, Charleston, SC 11:05 Panel Discussion 11:20 LUNCH 12:20 Empiric Therapy for Invasive Candidiasis in the ICU: Who, When, How? S. Jacobs, MD, New York, NY 12:45 Viruses in theCritically Ill:BystandersorOffenders? C. Dela Cruz, MD, PhD, ATSF, New Haven, CT 1:10 Is There a Right and Wrong Way to Use Procalcitonin in the ICU? C. Rhee, MD, MPH, Boston, MA 1:35 Panel Discussion 1:50 Break 2:05 Lung Infections on Biologics: What to Consider Before and During Therapy? K.L. Winthrop, MD, MPH, Portland, OR 2:30 What Has Changed in the Landscape of Pneumocystis Pneumonia? K.A. Crothers, MD, Seattle, WA 2:55 ATS Fungal Diagnosis Guidelines: How Do They Apply to the Immunocompromised? C.A. Hage, MD, ATSF, Indianapolis, IN 3:20 Panel Discussion 3:35 Post-Test C.A. Hage, MD, ATSF, Indianapolis, IN 3:50 Conclusion R. Thomson, MBBS, PhD, Greenslopes, Australia CLINICAL POSTGRADUATE COURSE PG24 FULL CIRCLE OF PULMONARY EMBOLISM (PE) CARE: ACUTE TO CHRONIC AND EVERYTHING IN BETWEEN Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited. Member: $350 In-Training Member: $200 Non-Member: $425 In-Training Non-Member: $300 Assemblies on Pulmonary Circulation; Clinical Problems; Critical Care ATS 2020 • Philadelphia, PA 28 SATURDAY • MAY 16